3000+ Attendees, 450 Speakers, 12 Conference Tracks, 100+ Posters
 
MMTC15_Header  
MMTC M Header 

Cambridge Healthtech Institute’s Third Annual 

Predictive Preclinical Models in Oncology 

Delivering Reproducible and Predictive Research Results

February 15-18, 2015 | Moscone North Convention Center | San Francisco, CA  
Part of the 22nd International Molecular Medicine Tri-Conference 

 

Predicting whether a potential new anticancer agent will be effective in patients remains a challenge. Despite tremendous progress in our understanding of cancer biology, the majority of novel anticancer therapies fail in Phase 3 clinical trials. This situation brings into question the quality of preclinical tumor models and predictability of preclinical studies in oncology. There is a critical need for models that allow to more effectively evaluate novel cancer therapeutics as well as to identify predictive biomarkers early in drug development. Cambridge Healthtech Institute’s Third Annual Predictive Preclinical Models in Oncology is designed to highlight the cutting-edge in vitro and in vivo preclinical tumor models and to facilitate a discussion about effective translational approaches in cancer research. 

Who should attend: Cancer Researchers working at Pharmaceutical and Biotech companies as well as Academic centers should attend this conference

Topics will include, but are not limited to: 

  • Case studies of preclinical trials designed based on model similarity to human cancer biology   
  • Modeling inter-patient response heterogeneity using PDX models 
  • Avatar models to guide patient therapy 
  • Translational PK/PD research 
  • Predictive biomarker identification in murine models
  • Genomic analyses in support of preclinical cancer research 
  • Phenotypic screening with PDX models
  • Spontaneous veterinary models  
  • Preclinical studies for combination cancer therapy 
  • Modeling primary, resistant and metastatic tumors
  • Mouse trials: following human clinical trial approaches 
  • Validation of animal models 
  • Immunocompetent models for preclinical assessment of cancer immunotherapy 
  • Syngeneic models for immunotherapy assessment  
  • Exploring possible combination of targeted therapy and immunotherapy
  • Novel 3D tissue models and their applications

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is July 18, 2014. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact:
Marina Filshtinsky, M.D.
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5406
E: mfilshtinsky@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z) 
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com 

 

 



Premier Sponsors:

Leica Biosystems 
 

 NanoString2   

 

Singulex 

 

Jackson Laboratory - small logo